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ated with a significant humanistic and economic burden. These results suggest
that the manifestation of the HCV burden, and the profile of the patients them-
selves, varied dramatically by country. Successful disease management should be
cognizant of region-specific unmet needs.
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OBJECTIVES:Todescribe the sex and sex communication experiences of females in
second cycle institutions METHODS: A cross sectional study involving the use of
structured questionnaire and interview guidewas conductedwith female students
in two selected secondary-level institutions in Bekwai, Ghana. Data was collected
from 391 randomly selected and consented female adolescent students aged 18
years or less in 2011. Data was analysed into descriptive statistics with statistical
significance set at 0.05 or less and at 95% confidence interval RESULTS: The study
revealed that 202/391(51.7) respondents had ever had sex, 134/202(66%) were cur-
rently having sex. Of 202 who had ever had sex, 151/202 (74.8%) discussed sex with
their friends while 96/189(50.8%) who had never had sex also discussed sex with
their friends. The top threemajor sources of sexual informationwas obtained from
friends, 187/391(47.8%), parents 85/391(21.7%) and teachers, 70/391(17.9%). A ma-
jority, 55.5%, as compared to 41.9% of the respondents, disagreed that parents talk
freely about sex. There were statistically significant associations between sex dis-
cussant and ever had sex (chi square  271; p0.01) and source of information on
sex and ever had sex (chi square  21.7; p  0.01). CONCLUSIONS: A majority of
female adolescent students are sexually active. Parents of female adolescents are
unpopular sources of information about sex and hardly do they discuss sexual
issues with adolescents. Understanding factors influencing parents’ willingness in
discussing sexual issues about sex could be helpful inminimizing sex related prob-
lems among female adolescent students.
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OBJECTIVES: Patients’ living with HIV/AIDS perceptions of their position in life in
the context of the culture and value systems in which they live and in relation to
their goals, expectations, standards and concerns were assessed using the HAT-
QOL. We explored the impact of socio-demographic profile on the quality of life
domains.METHODS: Consenting outpatients who met criteria were consecutively
selected. Socio-demographic characteristics of the patients were profiled. Health
related quality of life was determined in the domains of Overall function, Life
satisfaction, Health worries, Financial worries, Medication worries, HIV mastery,
Disclosure worries, Provider trust, and Sexual function. Quality of life scores were
computed on the standard scale of 0 - 100 and triangulated with a rated interval
scale of 1-5 suited for quantitative analysis. Association between rated scores and
each domain was explored using Students’ t-test and ANOVA at 95% confidence
interval. RESULTS: Four hundred and seven (407) patients (74males 333 females)
participated.Majority of the patients (147, 36.1%) aged 20 to 30 years and 239 (58.7%)
were notmarried. Also, 338 (83.0%) earned below$1500 pa and 303 (74.4%) had basic
education. HAT-QOL scores indicated: Overall function (89.96 5.62); Life satisfac-
tion (91.94  3.62); Health worries (87.06  4.28); Financial worries (81.00  3.95);
Medication worries (91.65  4.47); HIV mastery (71.00  3.11); Disclosure worries
(27.50 7.58); Provider trust (91.63 1.96); and Sexual function (70.25 3.52). Rated
scores were in congruence with HAT-QOL scores. Provider trust was associated
with gender, employment status, and educational level, (P 0.05). CONCLUSIONS:
Patients reported satisfactory quality of life in the various domains except disclo-
sure worries, indicating concerns for discrimination and stigmatization. Provider
trust was associated with gender, employment status, and educational level. Sex-
ual function was associated with gender and age of the patients.
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OBJECTIVES: Patient-reported outcome measures are central to the evaluation of
Health-Related Quality of Life (HRQL), medical care and treatment regimens. Such
measures depart from traditional clinical assessments as they are based on issues
known to be of primary importance to patients. The objective was to select PRO
questionnaires for a pharmaco-epidemiological, observational study conducted in
France to highlight the impact of HZ and PHN on patients’ daily life and Health
Related Quality of Life (HRQoL) over a 12-month follow up. METHODS: Specific
instruments review of existing PRO/HRQLwas performed trough Pubmed and PRO-
QOLID® databases; in order to select questionnaires able to measure the level/type
of pain and HRQL perceived by the patients. The main criteria taken into account
for the selection of PROmeasureswere the appropriateness, reliability, validity and
ability to detect change (patients’ follow-up assessments of PHN and HRQL were
performed by telephone calls). RESULTS: Among the existing questionnaires, five
measures were selected: Neuropathic Pain Diagnostic Questionnaire (DN4), Neu-
ropathic Pain Symptom Inventory (NPSI) designed to measure the quality and se-
verity of neuropathic pain, Zoster Brief Pain Inventory (ZBPI) tomeasure the impact
of pain and discomfort caused by HZ or PHN, the SF-12 Health Survey and the
Hospital Anxiety and Depression Scale (HADS). All measures were available in
French and the overall length of the interview was acceptable. The ZBPI, scores
have shown impact on general activity and sleep. The mean scores of Depression
and Anxiety were significantly higher in patients with PHN. The physical andmen-
tal component summaries of the SF-12 were lower in patient with persistent PHN
than the patients without PHN. CONCLUSIONS: Using PRO measures in observa-
tional studies is well accepted by the scientific community. However, a rigorous
methodology for the selection of PRO measure is mandatory to ensure medical
relevance and fulfillment of protocol requirements.
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OBJECTIVES: Selection of an appropriate patient-reported outcome (PRO) instru-
ment for clinical trials requires a clear understanding of the instrument’s sensitiv-
ity to an intervention’s anticipated impact. The purpose of this study was to exam-
ine the responsiveness of 2 health-related quality of life (HRQL) instruments
among HIV-infected adults: the disease-specific Medical Outcomes Study HIV
Health Survey (MOS-HIV), and a genericmeasure, the EQ-5D.METHODS:A targeted
literature search identified clinical trials administering the MOS-HIV or EQ-5D and
evaluating HIV-infected adults from 2005-2010, or earlier when fewer than 5 stud-
ies were identified. Key data abstracted from each study included study type, treat-
ment regimen(s), PRO results, and effect size (either reported or calculated). Effect
size was calculated as the difference between baseline and follow-up mean scores
divided by the baseline standard deviation and was interpreted as small (d0.20),
medium (d0.50), and large (d0.80) [Cohen 1988]. RESULTS: In the past 5 years,
the MOS-HIV was administered in 12 trials. Significant differences were observed
between groups and over time in physical health summary (PHS) and mental
health summary (MHS) scores (p0.05) in subjects switching therapy after experi-
encing adverse events (grade 2 or higher). Effect sizes were medium (0.55 and 0.49
for PHS and MHS, respectively) among treatment-naïve adults beginning therapy
(n2 studies), but negligible among treatment-experienced adults (0.04 and 0.13 for
PHS and MHS, respectively; n3 studies). The EQ-5D was administered in 5 trials
during the past 10 years. The EQ-5D was responsive to occurrences of adverse
events (n2 studies), opportunistic infections (n1 study), and demonstrated
small-to-medium effect sizes (range 0.30-0.50) in treatment-experienced patients
(n1 study). CONCLUSIONS: In-depth review of PRO study results showed that
both theMOS-HIV and EQ-5Dwere responsive to changes in HIV-infected patients.
These instruments may be used either individually or together in clinical trials to
demonstrate changes in HRQL.
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OBJECTIVES: Universal vaccination against Hepatitis B virus (HBV) is effective to
control HBV infection. Hepatitis B immunoglobulin (HBIG) given to neonates helps
further reduce HBV transmission. The objectives are 1) to compare the cost-effec-
tiveness of four strategies for HBV screening and HBIG treatment in settings with a
universal vaccination policy, and 2) to identify cost-effective HBIG strategies for
different HBV prevalence rates. METHODS: We used Taiwan as an example and
developed a decision analysis model to estimate the clinical and economic out-
comes of HBV infection for a hypothetical cohort of 100,000 newborns. The four
strategies were 1) Strategy V: vaccination only for all neonates, no screening or
HBIG treatment,; 2) Strategy S: maternal screening HBsAg, HBIG given for neonates
born to HBsAg-positive mothers; 3) Strategy E: maternal screening HBeAg, HBIG
given for neonates born to HBeAg-positive mothers; and 4) Strategy S&E: maternal
screening HBsAg then HBeAg, HBIG given for neonates born to HBeAg-positive
carrier mothers. RESULTS: In Taiwan, if willing-to-pay (WTP) over $3000 to avert a
case of HBV infection, Strategy S would provide the best protection. For WTP be-
tween $1500-3000, Strategy E would be preferred at HBV prevalence  14%, fol-
lowed by Strategy S&E at prevalence 5-13%, and finally Strategy S at prevalence 
5%. For WTP less than $1,500, Strategy V would be optimal. CONCLUSIONS: The
optimal strategy is a function of WTP and HBV prevalence which usually declines
gradually following the launch of immunization. This study provides a roadmap for
considering alternative approaches to targeting HBIG treatment after the introduc-
tion of HBV vaccine.
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